Aptevo Therapeutics Inc. 8-K

What Happened

• Aptevo Therapeutics Inc. announced new interim clinical data for mipletamig given in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients. The company issued a press release dated March 10, 2026 and filed an 8-K on March 11, 2026 to disclose the announcement.

Key Details

• Filing: Form 8-K dated March 11, 2026 (Item 8.01 – Other Events; Item 9.01 – Exhibits).
• Press release: Issued March 10, 2026 and attached as Exhibit 99.1 to the 8-K.
• Drug and regimen: Mipletamig administered in combination with venetoclax and azacitidine for newly diagnosed AML.
• Signature: Report signed by Marvin L. White, President and Chief Executive Officer, on March 11, 2026.

Why It Matters

• Clinical updates are material for biotechnology investors because interim data can affect the perceived value of Aptevo’s pipeline, potential development timelines, and partnering or financing prospects. This 8-K formally notifies the market that Aptevo has new interim data for a key program; investors should review the March 10 press release (Exhibit 99.1) for the detailed results and consider any subsequent company updates or regulatory disclosures.